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1. Introduction 
Pharmaceutical tablets are subject to special regulations regarding their quality. Obvious 
examples are requirements for tablet performance in terms of pharmacological effect, which 
is closely connected to the uniformity of drug substance content in each tablet, to the 
disintegration properties of the tablet into smaller particles after intake, and to the rate of 
dissolution of the drug substance from the tablet or particles (drug release). For each 
product on the market, a set of quality criteria and their specific limits are defined by the 
relevant regulatory health authorities, e.g. Food and Drug Administration (FDA) in the 
USA, or European Medicines Agency (EMA) for Europe.  
Following the steps of the development of a new tablet, we distinguish six main phases:  
a. design and synthesis of the new pharmaceutically active drug substance (active 
pharmaceutical ingredient, API),  
b. characterisation and quality assurance of the bulk raw materials, i.e. the API and 
additives (excipients), 
c. optimisation of the composition of the formulation with respect to API and excipients, 
d. scale-up to larger throughput (industrial scale),  
e. optimisation and validation of the processing steps for the manufacturing; monitoring 
processing steps during manufacture,  
f. quality assurance of the finished product, the tablet. 
Tablets have been produced for more than 100 years in large quantities, and their quality 
has always been an issue; therefore the technical factors that influence tablet properties have 
been studied extensively. It has immediately become obvious that the number of factors is 
large and that there is a lot of interaction between them. Therefore, pharmaceutical 
development in general, and tablet manufacture in particular, have been one of the first 
areas where factor analysis and Design of Experiments (DoE) have been introduced.  
The current international regulations for pharmaceutical products, namely the ICH 
(International Conference of Harmonisation) guidelines (ICH Q8) including Quality by 
www.intechopen.com
 
Principal Component Analysis – Multidisciplinary Applications 
 
44
Design (QbD) approaches together with Process Analytical Technology (PAT) initiated by 
the FDA in 2004 have drawn even more attention to the use of state-of-the-art science and 
technology (PAT-Initiative, 2004; Guidance for industry, 2004). Improvement of the 
manufacturing of drug preparations is thereby initiated with the aim to replace end-product 
control of random samples by real-time quality control of every single item.  
It is nowadays a prerequisite for the registration of a new tablet preparation to show how 
the use of systematic studies during the development phase has led to a good 
understanding of the processes, how rational decisions have been made during the 
development process with regard to an optimum product, how the manufacturing 
processes can be controlled within set limits, and to estimate the robustness of the 
processes, i.e. what a certain variability of any ingoing parameters means for the 
properties of the final product. Therefore, it is very common to integrate factor analysis 
and multivariate projection methods such as PCA in all stages of pharmaceutical 
development and manufacture in general. However, tablets are a particularly prominent 
example thereof, because all stages from the preparation of the bulk powder, granulation, 
compression and coating widely influence the properties of the final marketed product. 
Systematic studies within a reasonable design spaces and a good scientific understanding 
of the processes reduce uncertainty and create the basis of flexible and risk-based 
regulatory decisions. Therefore, chemometric methods, such as DoE and multivariate 
analysis (MVA) are – if nothing else of necessity - frequently and extensively used in 
pharmaceutical product and process development. 
This chapter focuses exclusively on fundamental studies for the rational development of 
tablet formulations of general interest. Therefore, it will restrict to examples of commonly 
used excipients and to simple manufacturing methods. The interested reader is addressed to 
specialized textbooks for further reading about production technologies and quality 
assurance (e.g. Bauer-Brandl & Ritschel, 2012; Gad, 2008). 
2. Definitions and background information 
2.1 Pharmaceutical tablets  
Tablets contain both the active pharmaceutical ingredient, API, for obvious reasons, and 
different types of excipients to generate both manufacturability and product performance. 
In a standard procedure, both types of powders (API and excipients) are homogeneously 
mixed and granulated, the granules finally mixed with more excipients (glidants, lubricants, 
etc), upon which the final blend is compressed into tablets. The tablets will, in contact with 
water or fluids of the gastrointestinal tract, disintegrate into the granule/powder again, 
before the drug substance is released. Figure 1 depicts the basic steps of production of a 
standard tablet and processes upon contact with water or gastrointestinal fluids. 
2.2 Quality of tablets  
For pharmaceutical tablets, quality has many aspects: We have to distinguish between the 
tablets as such, and the drug product, which includes the packaging and the product 
description. Table 1 lists some of the most important quality criteria for a tablet product. 
Any of these may be used as a quality attribute for optimisation of a tablet product.  
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Fig. 1. Schematic drawing of the basic production steps of a tablet (upper arrows), and the 
disintegration and release of drug from the tablet (lower arrows) 
Appearance of the 
tablets 
Composition Properties of 
 the tablets 
Properties of the 
drug product 
Shape  Identity of drug 
substance(s) 
Mechanical strength Outer package 
identity 
Dimensions: Height, 
Diameter 
Additives 
(excipients) 
Ease to break Label identity 
Engravings (Symbols, 
numbers, etc) 
Quantitative drug 
content per tablet 
Disintegration 
behaviour in water 
Leaflet identity 
Colour  Total mass per 
tablet 
Drug release rates in 
different media 
Tamper-proof 
inner package 
Surface appearance 
(shiny, smooth) 
Coating 
composition  
(mouth feeling) Safe storage 
conditions  
No specks,  
no spots 
Coating thickness No capping, 
no layering 
No sign of 
tampering  
No cracks,  
no chipping 
  No defect 
Table 1. Some important quality criteria of tablets as a drug product 
For the marketing of a drug product, all the specifications need to be authorized by the 
respective local health authorities. Thereby, the actual values of quality requirements are 
defined for each single product individually, depending on the significance of the different 
criteria for this particular product and on special rules in the respective country. 
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2.3 Tablet development  
The development of a new tablet formulation and production process takes its start in the 
properties of the active ingredient(s). For formulation (composition) development, it is of 
importance to choose the most suitable set of excipients to mix with the APIs to obtain a 
tablet product of certain quality attributes. In process (handling) development, including the 
choice of the processing method, all the processing parameters (such as temperatures, 
sequence of addition of excipients, mixing conditions, duration of the processing steps etc.) 
contribute to rather complex interrelated relationships between critical process parameters 
and quality criteria. The entire production process is typically divided into several steps, 
each of which is individually optimised. 
Figure 2 shows general principles of how to control step-wise production. Choice of 
production method, optimisation of production steps, and control schemes have 
traditionally been handled by practical experience and by empirical development methods.  
 
Fig. 2. Schematic drawing of production step control 
2.4 A Brief overview of processes and parameters involved 
In the following the elaboration will be restricted to basic tablets produced by a standard 
technique. Table 2 shows the impact of the main production steps on the quality of standard 
tablets. A schematic depiction of the sequential arrangement of some commonly used 
processing steps for standard tablets is given in Figure 3 together with a selection of related 
important processing parameters. Furthermore, monitoring of some machine parameters is 
also included. 
2.5 The combination of DoE and MVA  
Statistical experimental design, also called design of experiments (DoE), is a well-established 
concept for planning and execution of informative experiments. DoE can be used in many 
applications connected to tablet development and manufacture. One may, for instance, use 
designs from the fractional factorial or central composite design families, when addressing 
problems in which the influence of process parameters (temperature, pressure, time, etc.) on 
product properties are monitored and optimized. Another main type of DoE application 
concerns the preparation and modification of mixtures or formulations, where the challenge 
is that the parameters are not independent but components add up to 100%. This involves 
the use of mixture designs for changing composition and exploring how such changes will 
affect the properties of the formulation (Eriksson et al., 1998). Also designs in which both 
process and mixture factors are varied simultaneously are frequently seen. For tablet 
development and manufacture, one or several of the process parameters and/or critical 
quality attributes listed above, are likely to be used as optimization goals. 
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Tablet Property Raw 
materials 
Granulation Drying Final 
blending 
Compression 
Dimensions ++ + + + ++ 
Appearance + + ++ + ++ 
Total mass per tablet + + ++ ++ - 
Drug content (assay) + + + ++ - 
Mechanical strength ++ ++ ++ ++ ++ 
Disintegration ++ ++ + ++ ++ 
Drug release rate ++ ++ + ++ ++ 
Stability; degradation + - ++ - - 
Microbiological 
quality 
++ - ++ - - 
+: important;  ++: very important; -: important in special cases only 
Table 2. Impact of Processing Steps on Tablet Quality 
 
Fig. 3. A schematic view of the course of main processing steps, processing parameters and 
monitoring features of tablet production 
Multivariate projection methods, such as principal component analysis (PCA) and partial 
least square (PLS) regression, are combined with DoE in formulation or process 
development for screening of a large number of influence parameters (fractionated factorial 
design) and further optimization of the important parameters, to study their interactions 
and possible non-linear behaviour (central composite design, Box Behnken, D-optimal, 
mixture designs). 
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3. PCA in exploring new molecular entities  
QSAR and QSPR respectively (quantitative structure activity/property relationship) 
interlink biological effects or physical properties to the molecular structure of the respective 
substance. The best known example is the design and synthesis of new drug molecular 
entities in medicinal chemistry where the aim is that the drug molecule (API) interacts with 
the molecular structures at the site of action (e.g. receptors, enzymes). Another important 
step for a drug substance to act as a useful remedy is the uptake of such molecules into the 
body, which is a prerequisite to reach the receptor – has led to systematic PCA based studies 
of structure permeability relationships (e.g. intestinal barriers for the uptaker of oral drugs, 
or transport though the blood brain barrier; BBB partitioning).  
Similar PCA methods have also been applied in formulation development by means of 
calculated quantum chemical descriptors for excipients (see Section 4.1.1.). 
4. PCA in formulation development and processing  
For the development of the formulation (composition) and the process (handling), all the 
experimental parameters during the entire manufacturing (such as chemical composition, 
processing steps, and processing conditions) contribute to the properties of the final 
product. In the following, examples of recent studies are briefly discussed, organized 
according to  separate steps, although the entire flow of processing steps affects the product 
properties.  
4.1 Excipient choice 
As a rule, excipients have multiple functionality depending on the types of (other) materials 
present in the formulation, composition of the blends, and processes used. Well-known 
examples are filler-binders and lubricant-glidants.  
A set of basic studies including four groups of excipients (filler, binder, disintegrant, 
lubricant) with several examples for each, in total almost one hundred excipients, were 
screened with respect to tablet properties (good mechanical strength and short 
disintegration time) (Gabrielsson et al., 2000; 2004). DoE combined with PCA and PLS were 
used in screening and optimisation: PCA provides a general overview over relationships 
and PLS models quantify the relationships between excipient properties and responses 
(tablet properties). Such mapping of excipients can be useful for selection of the appropriate 
material for a new formulation. 
4.1.1 Examples of functional polymers as excipients 
Microcrystalline cellulose (MCC) is a frequently used excipient with filler/binder function. 
It is derived from native cellulose through hydrolysation and purification. Using DoE and 
stepwise multiple regression analysis, particle properties and the functionality of different 
MCC products can be quantitatively related to the hydrolysis conditions (Wu et al., 2001). 
As another example the formulation of pectin pelletisation masses using different 
granulation liquids is shown in the form of a PCA score plot mapping the experimental 
area. Correlation between properties of the masses and the respective additives was found 
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using quantum chemical molecular descriptors (QSAR) of the additives. Partial least square 
regression methods, mainly PLS-2 models, were used to quantify the effects (Tho et al., 
2002). Based on the models, a rational choice of the composition of the formulation  
can be made. 
4.2 Mixing / blending 
Homogeneous powder blends are a prerequisite of the predefined dose of API per tablet. In 
optimized blending processes, homogeneity of the bulk is achieved. 
However, segregation tendencies – becoming significant even for initially homogeneous 
bulk powder blends when these materials are transported - are even more important to 
consider. The effect of powder properties on segregation was studied, and PCA models 
developed to connect material properties to segregation tendency. A comparison of the 
multivariate approach and univariate approaches reveals that the latter leads to incomplete 
models (Xie et al., (2008)). 
4.3 Particle size and powder flow 
Multivariate latent variable methods have also been applied to mixture modelling of 
pharmaceutical powders. Particle size distribution was shown to predict powder flow 
(Mullarney and Leyva, 2009). Particle size distribution along with particle shape information 
has also been used to predict bulk packing and flow behavior (Sandler & Wilson, 2010).  
4.4 Granulation 
Wet granulation is classically done in high shear mixers or in fluidized bed equipment, or in 
a recent approach as a continuous process.   
A basic investigation of general interest into the fluid bed granulation process is described 
by Dias and Pinto (2002), who used DoE and cluster analysis to find the relevant processing 
parameters and relations to product properties. 
Another basic study of the fluid bed granulation process is described by Otsaka et al. (2011). 
PCA was first used to describe the relationships between a set of granule properties and to 
identify the properties that produce optimum tablet properties. In a second step, regression 
modelling was used to optimize the granulation conditions.  
For wet granulation in high shear mixers, there are two different possibilities: The first one 
is a separate wet massing step and subsequent drying in another machine. The alternative is 
a single-pot set-up, where the drying step can be conducted in the same piece of equipment. 
Giry et al. compare these two processes (Giry et al., 2009) with respect to product properties 
using a set of formulations. This is a typical DoE and PCA application. Both processes led to 
products with only slight differences in properties. However, the robustness of the processes 
was different.  
An alternative to wet granulation methods is dry granulation, basically by compression of 
dry powder blends to make granules. A dry granulation process conditions was studied 
within a PLS framework to predict selected granulation properties (Soh et al. 2008). 
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4.5 Drying 
In-line monitoring of the water content is essential in order to find the end point of the 
drying step for optimum water content of granules. NIR (near infrared) spectroscopy is 
particularly sensitive to water content, and using PCA/PLS models enable prediction of the 
actual water content. In addition, the NIR spectra are also sensitive to other granule 
properties such as particle size. However, in bulk material of a wide particle size, the actual 
water content of the granules varies significantly with size. Nieuwmeyer et al. (2007) 
developed a method for characterization of both water content and granule size during fluid 
bed drying based on NIR spectroscopy.  
4.6 Final blend; lubrication 
The final blend is typically produced by blending solid lubricant into the granules. The 
problem with too long mixing times (“overmixing”) is that lubricant particles scale off and 
cover too much of the granule surface, which leads to weak tablets. As an example to 
monitor the blending profile (the degree of lubricant coverage) over time, and correlate this 
to tablet hardness, NIR was used (Otsuka & Yamane, 2006). Principal component regression 
was employed to model and predict the hardness of the tablets.  
4.7 Tablet compression 
Compression of the materials into tablets is a complex processing step, which is not yet fully 
understood. Amongst others, influences of particle size, shape, and structure on the 
deformation mechanism are difficult to separate and quantify. It has been shown that it is 
possible to derive basic material deformation characteristics during the compression step 
from in-line processing data using model materials (Klevan et al., 2010). Due to the 
complexity of the deformation of powder beds and the large number of parameters that may 
be regarded, screening of such in-line derived parameters for the most useful set of 
parameters is necessary in order to avoid over-determined functions (Andersen at al., 2006). 
Examples are discussed using a set of commonly used excipients of most diverse properties 
within the useful materials (Haware et al., 2009a; Roopwani & Buckner, 2011). The effect of 
particle engineering with regard to the tablet properties, such as tablet tensile strength, 
studied by PLS models (Otsuka & Yamane, 2006; Haware et al., 2010) using cross validation 
(jack-knifing). Prediction of tablet mechanical properties using PLS model can be made from 
NIR spectra of the blends (Otsuka & Yamane, 2009) or from in-line compression parameters 
derived on examples of very similar properties (Haware et al., 2009b). 
Figure 4 shows a PCA biplot as an example how particle properties of different 
commercially available lactose qualities spread out in a design space.  The data together 
with in-line compression parameters were used to predict the mechanical strength of tablets 
made with different blending ratios (formulations) and under different experimental 
conditions of compression (Haware et al., 2009b). 
4.8 Combination of processes 
Polizzi and García-Munoz (2011) proposes a quantitative approach to simultaneously 
predict mechanical properties of particles, powders, and compacts of a pharmaceutical 
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blend, based on the raw materials. They used a two-step, multivariate modeling approach 
created using historical physical data of APIs, excipients, and multi-component blends. The 
physical properties for each individual component were first transformed using a PCA 
technique to place them in a multivariate design space and capture property correlations. 
The scores from these PCA models were then weighted by the blending ratios prior to PLS 
regression versus actual measured blend properties. This method produced a complete 
prediction of all the material properties simultaneously which was shown to be superior to 
the prediction performance observed when applying linear ideal-mixing. 
 
Fig. 4. Example of a PCA biplot showing powder characteristics of commercially available 
lactose grades spread out in the design space (modified after Haware et al. 2009b).  
5. PCA in quality assurance of tablets 
5.1 Spectroscopic methods 
Molecular vibrational spectroscopy techniques, such as infrared (IR), near infrared (NIR) 
and Raman, are characterisation methods that have been applied to monitor both physical 
and chemical phenomena occurring during the processing as well as for off-line 
characterisation of raw materials and end-products. These techniques produce data of high 
dimensionality, since each sample is described with hundreds or even thousands of 
variables (wavelengths). Multivariate projection techniques, such as PCA are frequently 
combined with spectroscopic methods to enable detection of multivariate relationships 
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between different variables such as raw materials, process conditions, and end products. 
Also well-known spectroscopic methods that are easier to interpret, e.g. UV (ultraviolet) 
spectroscopy and X-Ray diffraction, have been suggested to benefit from the use of PCA. 
Both NIR and Raman spectroscopic measurements can be done in a very fast (within 
seconds) and non-destructive way, making them suitable tools for real-time process 
monitoring. They are frequently used for in-line monitoring of processes, e.g. particle size 
growing during granulation or the water content in the granule (Räsänen & Sandler, 2007; 
Rantanen 2007). NIR is also used for monitoring the final quality of the single tablets, 
because it is possible to quantify the active ingredient in a none-destructive manner (Tabasi 
et al., 2008), and can be applied to indentify counterfeit drugs (Rodionova et al., 2005). 
Another example is the prediction of tablet hardness based on NIR spectra of powders with 
lubricants (Otsuka & Yamane, 2006, 2009). For further applications of vibrational 
spectroscopy and chemometric methods in pharmaceutical processes, the reader is referred 
to the reviews by Gendrin et al. (2008), De Beer et al. (2011) and Rajalahti & Kvalheim (2011). 
5.2 PCA in drug release 
Sande and Dyrstad (2002) used PCA/PCR for parameterisation of kinetic drug release 
profiles, and showed that the combination of PCA and SIMCA was useful for classification 
of formulation variables based on the entire profiles. Also multi-way principal component 
analysis (MPCA) has been used to study entire tablet dissolution profiles and detection of 
shifts upon accelerated stability (Huang et al., 2011). Korhonen et al. (2005) calculated 
physicochemical descriptors (using VolSurf software) of different model drugs and 
correlated those to the respective dissolution profiles from matrix tablets. Again, the entire 
dissolution profiles without any parametric curve fitting were used in the models. This is a 
great advantageous, since the contribution of different variables tends to change in the 
course of the drug release event due to the dynamic nature of drug release from the  
matrix tablets. 
Another example of the non-parametric curve description of drug release from a sustained 
release matrix is the approach suggested by Kikuchi and Takayama (2010). They use non-
parametric descriptors and non-parametric differences between release curves for 
optimization (24 h linear release) and prediction. Surface plots are used for prediction of 
composition of the matrix tablets. 
6. Monitoring and sensors 
Combination of instrumentation and multivariate analysis provides powerful tools for 
effective process monitoring and control enabling detection of multivariate relationships 
between different variables such as raw materials, process conditions, and end products. 
Multivariate methods play an important role in process understanding, multivariate 
statistical process control, default detection and diagnosis, process control and process  
scale-up.  
Continuous monitoring of process parameters allows continuous regulation and adjustment. 
Given rational development of the parameters as a background, a statistical process control 
is possible in order control the variation in a process within specification limits. 
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Furthermore, non-statistical variation caused by a specific event can be identified and the 
special causes thereof studied, with a possibility to eliminate these for the future. 
In the case of tableting, continuous monitoring of the maximum compression force for each 
single tablet has been a standard in industrial production for more than 30 years. The force 
values are used as a measure for the individual tablet mass (and given homogeneity of the 
tableting material, also the dosing of each tablet). It is possible to sort out single bad tablets 
from the production line. A feedback loop needs to readjust the correlation between force 
and dosing based on sample analysis. By this, each tablet is held within the specification 
limits. Further development on tablet machine instrumentation includes measuring forces 
and displacements at different machine parts, and acoustic sensors in order to catch effects 
connected to lubrication problems. 
Statistical Process Control (SPS) is the best way to take advantage of real-time monitoring. 
Based on the experience from process development, upper and lower warning and control 
limits can be set, where predefined action is taken: further trend analysis, actual changing of 
parameters, searching for the cause of an outlier. Figure 5 illustrates how SPS may be 
implemented in process monitoring. Trending analysis and feedback loops are necessary 
features to readjust these limits if necessary. In cases where secondary measures are used, 
reassuring the calibration with other measures is frequently conducted on a regular basis. A 
typical example is the relationship between compression force and mass of tablets. This is 
directly connected to the bulk density of the tableting material, which may change during 
the course of the actual tableting process. In many cases increased density is observed over 
time due to bulk material transport in the machine combined with machine vibrations. The 
mass of the tablets therefore needs to actually be checked on a balance.  
 
Fig. 5. Principles of Statistical Process Control (SPS) based on process parameter monitoring 
Frequently used sensors based on NIR or Raman spectroscopy identify the chemical or 
physical variation between intermediates and products, particularly in the case of large 
numbers of samples: 
 particle size distribution of powders and granules, 
 granulation process monitoring, 
 powder mixing optimization, 
 scale-up of powder mixing,  
 tablet properties (e.g. drug content). 
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These methods can be used to collect all batch characteristics, model all batches, detect 
outliers, and check future batches against historic batch models (in-line monitoring). These 
are prerequisites to diagnose out-of-limit-batches. 
7. Future of tablet manufacture development 
Traditionally, pharmaceutical manufactures are batch-based production methods with 
sample-based end-product control. This includes a sampling procedure with all its 
drawbacks. The future will be in the real-time in-line monitoring during processing, in order 
to be able to control the processing steps rather than end-point controls on the product. This 
will consequently lead to continuous production processes, which can be conducted in 
equilibrium. Continuous granulation has been developed already for a number of processes, 
including fluid-bed granulation, extrusion, and roller-compaction. These days, complete 
continuous production lines from the powder to the tablet are being introduced to  
the market.  
The vision is to have such continuous production all the way from API synthesis to the final 
drug product ready for the market. The advantage will be a controlled and stable process 
with less product variation compared to traditional batch-based production methods. 
Furthermore, sample-based post-production quality control will be unnecessary and 
discarding or reworking of bad batches will not happen again. The real-time-release of the 
product will also become possible. 
8. Conclusion 
Although pharmaceutical tablets have been produced for more than 100 years on an 
industrial scale, there are up to day a number of unresolved challenges in tablet 
development, manufacturing and quality assurance. The basic factors that influence the 
product properties are widely known. However, depending on the individual composition 
of the tablet, numerous factors may have different impact on product quality. Furthermore, 
there is commonly a large interaction between many of these factors. Depending on 
composition, processing conditions for the different steps and environmental conditions the 
properties of the final bulk material (tableting blend) can differ widely. The actual tablet 
compression step, again committed to numerous processing factors, in addition would have 
large impact on the product quality. These complex relationships open a multivariate 
perspective and require suitable statistical methods.  
For the tableting procedure, the steps that have been studied include powder blending, 
granulation, particle egalisation, lubrication, compression, coating, and drug release studies. 
Such step-wise studies have brought light into the impact of the parameters and their 
interactions and increased the understanding of the respective processes.  
Pharmaceutical products underlie special requirements for their quality set by the health 
authorities. Therefore, the pharmaceutical development has been one of the first areas where 
factorial analysis and PCA/PLS have even become compulsory.  
Moreover, the requirements for pharmaceutical drug products are under ongoing revision. 
It is a general trend that the requirements set higher standards with each new revision in 
order to assure safety and efficacy of the products.  Some of the most important recent 
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developments are the introduction of “Quality by Design” and PAT. It is a prerequisite to 
understand the processes, factors and interactions for the entire production line. Figure 6 
depicts how the statistical tools are related to each other, and used interconnected in tablet 
development, manufacture and quality assurance. 
 
Fig. 6. A schematic overview of which statistical tools mainly are used in tablet 
development, manufacture and quality assurance 
The development in the regulatory guidelines combined with new technology has found its 
expression in the efforts towards continuous production of pharmaceutical products, and in 
the forefront thereof the tablet manufacture due to both its relevance and complexity.  
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